News | September 17, 2009

Elixir Medical Bioabsorbable Polymer Drug-Eluting Stents Featured at TCT 2009

September 17, 2009 – Elixir Medical Corp. said today its stent systems using bioabsorbable polymers will be featured in multiple sessions at the 21st annual Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2009), Sept. 21-25, in San Francisco.

Clinical results from the company’s Novolimus and Myolimus eluting stent systems with durable and bioabsorbable polymers will be discussed in the following sessions:

• “Single center, first-in-man study of the Elixir novolimus-eluting coronary stent system with durable polymer: 24-month clinical safety and efficacy results,” Alexandre Abizaid, M.D., Ph.D. 8-10 a.m., Poster Session Hall D, Tuesday, Sept. 22.

• “The Elixir Bioabsorbable Polymer Myolimus-Eluting Stent Program,” Lecturer: Bernhard Witzenbichler, M.D., 2:16 p.m., DES Summit, room 104, Tuesday, Sept. 22.

• “The Elixir Bioabsorbable Polymer Novolimus-Eluting Stent Program,” Lecturer: Alexandre Abizaid, M.D., Ph.D., 2:23 p.m., DES Summit, room 104, Tuesday, Sept. 22.

For more information: www.elixirmedical.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Tryton Medical, Side Branch Stent, first U.S. commercial case, New York-Presbyterian Hospital, Columbia University Medical Center
News | Stents Bifurcation| March 31, 2017
Tryton Medical Inc. recently announced that the first U.S. commercial case using the Tryton Side Branch Stent was...
Sponsored Content | Videos | Stents Bioresorbable| March 30, 2017
Stephen Ellis, M.D., professor of medicine and director of interventional cardiology at Cleveland Clinic, discusses t
Overlay Init